Quantcast
Last updated on April 19, 2014 at 9:20 EDT

PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva’s Hlovovec Production Facility to Wood Pharma Holding

December 19, 2012

OXFORD, England, December 19, 2012 /PRNewswire/ –

PharmaVentures is pleased to announce that it has acted as transaction advisors and
sale process executioners for Sanofi. The current deal covers Sanofi’s divestment of its
Zentiva subsidiary’s production plant in Hlohovec, Slovakia. Under the terms of this
agreement, Sanofi will sell to Wood Pharma Holding the production, packaging and
distribution part of its Zentiva business covering Active Pharmaceutical Ingredients
(APIs) and Drug Products activities. The sale includes transfer of the production
facilities and employees. Future co-operation in the purchase of drug products and APIs
produced by Wood Pharma Holding in Hlohovec in the next five years has also been agreed.

This divestment follows the 2010 sale of Sanofi’s two European facilities
(Porcheville, France and Alnwick, United Kingdom) to Covance where PharmaVentures acted as
exclusive advisors to Sanofi. .

PharmaVentures continues to strengthen its considerable experience in the M&A field
including divestments of manufacturing and R&D businesses. Fintan Walton, CEO,
PharmaVentures Ltd said: “PharmaVentures is delighted to have worked with Sanofi again in
finding a new buyer for one of their facilities. This is a fantastic outcome for the
Hlohovec site and for the Slovakian Pharmaceutical industry as a whole. Not only does this
deal safeguard jobs at Hlohovec, but it offers the prospect of expansion of the existing
business and further job opportunities for the region.”

Over the past 21 years, PharmaVentures has acted as advisor to over 600 global
pharmaceutical and biotechnology clients in transactions covering licensing, merger,
acquisition, divestment and joint venture activities for companies.

About PharmaVentures

PharmaVentures is a premier transaction advisory boutique; a world leader in
partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist
experience, deal analytics and network of contacts among innovators and large pharma makes
us uniquely placed to support your business in all aspects of deal making and strategic
planning. PharmaVentures is well known for its deep insight into deal structures and its
success for generating partnering interest.

Find out more http://www.pharmaventures.com

Our services include:

        - M&A (divestments, mergers, acquisitions and strategic transactions)
        - Strategy (commercialisation, deal strategy, due diligence, market entry)
        - Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
        - Licensing (in and out licensing)
        - Expert Testimony (patent infringement, deal disagreements, taxation,
          determining damages)

Now in its 21st year, PharmaVentures is based in Oxford, UK, and employs over 17
people.

        For further information, contact:
        Dr Fintan Walton
        CEO
        PharmaVentures Ltd
        +44-1865-332700
        enquiries@pharmaventures.com

SOURCE PharmaVentures


Source: PR Newswire